HLA-B and toxic epidermal necrolysis: Hence, as a follow-up to issuance of the DHCPL, we have been tracking HLA-B*15:02 test orders and medication usage in addition to the usual pharmacovigilance role of monitoring the number of CBZ-associated SJS/TEN cases.